drug · antibody
patient view →nivolumab
Marketedupdated 2mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $9.3B
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.
indications
investigational
NSCLCProstate CancerColorectal CancerMelanomaDLBCL
targets
Programmed cell death protein 1
all catalysts(86)
approval · 83
phase 1 2 completion · 1
phase 1 initiation · 1
phase 2 completion · 1
comments(0)
5-min edit window · permanent after that